| __timestamp | Neurocrine Biosciences, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 94231000 |
| Thursday, January 1, 2015 | 81491000 | 146394000 |
| Friday, January 1, 2016 | 94291000 | 188272000 |
| Sunday, January 1, 2017 | 121827000 | 166707000 |
| Monday, January 1, 2018 | 160524000 | 401843000 |
| Tuesday, January 1, 2019 | 200000000 | 560909000 |
| Wednesday, January 1, 2020 | 275000000 | 722343000 |
| Friday, January 1, 2021 | 328100000 | 771182000 |
| Saturday, January 1, 2022 | 463800000 | 877090000 |
| Sunday, January 1, 2023 | 565000000 | 877387000 |
| Monday, January 1, 2024 | 731100000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Sarepta Therapeutics consistently outpaced Neurocrine Biosciences, with R&D expenses growing by approximately 830% compared to Neurocrine's 1,117% increase. By 2023, Sarepta's R&D spending reached nearly 880 million, while Neurocrine's was around 565 million. This strategic focus on R&D highlights the companies' dedication to advancing their therapeutic pipelines. As the biotech industry continues to evolve, these investments may prove pivotal in determining future market leaders. The data underscores the importance of sustained R&D efforts in driving innovation and maintaining a competitive edge.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending